Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report Discover which therapies are expected to grab the major mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Market Report Metastatic Castration-Resistant Prostate Cancer Overview Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In the context of...

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report

Discover which therapies are expected to grab the major mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Market Report

Metastatic Castration-Resistant Prostate Cancer Overview

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In the context of metastatic CRPC, the cancer exhibits diminished responsiveness to treatments aimed at lowering testosterone levels and has spread to other areas of the body. Manifesting growth signals, such as an elevation in prostate-specific antigen (PSA) levels, persist even when testosterone levels are low. Metastatic CRPC is associated with an unfavorable prognosis, leading to reduced survival rates. The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer.

Given the proximity of the prostate gland to the bladder and urethra, prostate cancer often presents with various urinary symptoms, particularly in its early stages. Depending on the size and location of the tumor, it may exert pressure on and narrow the urethra, impeding the normal flow of urine. Indications of mCRPC may include difficulties with urination, the presence of pain or blood in the urine, respiratory issues, swelling in the legs or pelvic region, as well as numbness or pain in the hips, legs, or feet. Additionally, bone pain is a common symptom.

Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmentation

As per DelveInsight estimates, the total diagnosed prevalent cases of mCRPC in the US were around  64K cases in 2022. The cases in the US are expected to increase during the study period, i.e., 2019–2032.

According to the DelveInsight estimation the total treated patients of mCRPC, in 2022, in the first line, mCRPC patient progression from first to the second line, and mCRPC patient progression from second to the third line and above in the United States was around 60K, 30K, and 14K cases respectively.

The mCRPC market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Metastatic Castration-Resistant Prostate Cancer Treatment Market 

The mCRPC therapeutic landscape is marked by intense competition, with numerous approved treatments currently available in the market and several promising therapies in the pipeline addressing unmet needs in both conditions. Until 2010, docetaxel stood as the sole treatment option for mCRPC, gaining approval in 2004 in combination with prednisone. Subsequently, patients failing first-line docetaxel faced a lack of standardized treatment options. In recent years, however, in the last few years, several drugs such as JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and others have received regulatory approval for mCRPC in the United States. This diversification has introduced more choices and improved the outlook for patients with mCRPC, reflecting advancements in the field.

In August 2023, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, reported that the US FDA granted approval for AKEEGA (niraparib and abiraterone acetate). This groundbreaking dual-action tablet, combining a PARP inhibitor with abiraterone acetate and administered alongside prednisone, is now authorized for therapeutic intervention in adult patients presenting deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as identified through an FDA-approved test. Additionally, in June 2023, the US FDA greenlit TALZENNA (talazoparib) for use in combination with enzalutamide, specifically targeting homologous recombination repair (HRR) gene-mutated mCRPC. In a parallel approval, LYNPARZA (olaparib) was also sanctioned by the US FDA, this time in combination with abiraterone, offering a treatment avenue for BRCA-mutated mCRPC.

To know more about mCRPC treatment guidelines, visit @ Metastatic Castration-Resistant Prostate Cancer Management 

Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies and Key Companies

Learn more about the FDA-approved drugs for mCRPC @ Drugs for mCRPC Treatment 

Metastatic Castration-Resistant Prostate Cancer Market Dynamics

The dynamics of the metastatic castration-resistant prostate cancer are expected to change in the coming years. In the foreseeable future, the advancement of therapies directed at specific mutations, such as PARP inhibitors, is anticipated to demonstrate enhanced efficacy. Companies are presently striving to establish a presence in the first-line setting, particularly in Taxane-naive environments, aiming to diminish the reliance on chemotherapy for individuals with mCRPC. The swift adoption of potential emerging therapies, characterized by superior clinical profiles and a focus on mutations like BRCA (e.g., PARP inhibitors), is expected to be rapid. The escalating prevalence of prostate cancer, driven by a rapidly aging population and heightened awareness, is poised to create a substantial window of opportunity for novel treatments.

Furthermore, the mCRPC pipeline is very robust; many potential therapies are being investigated for the treatment of mCRPC, and it is safe to predict that the treatment space will significantly impact the mCRPC market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the mCRPC market in the 7MM.

The treatment landscape in the third-line setting of mCRPC is currently crowded with PSMA-targeted radioligand therapies. PLUVICTO has already gained approval, while two other drugs, 177Lu-PNT2002 and TLX591 are in the Phase III development stage.

Quantitatively mCRPC pipeline seems to be quite strong. Antibody-drug conjugates (ADCs) developed by companies such MacroGenics (MGC018) and Daiichi Sankyo (DS-7300) have both displayed encouraging results in clinical trials involving patients with mCRPC. 

However, several factors may impede the growth of the mCRPC market. The CRPC landscape is nearly saturated owing to the approval of multiple therapies in this segment. Moreover, the emergence of new therapies targeting this area contributes to a highly competitive environment, potentially constraining the adoption of these emerging treatments. Meanwhile, Androgen Deprivation Therapy (ADT) remains a fundamental cornerstone in prostate cancer treatment. Healthcare authorities are anticipated to actively manage the pricing and utilization of high-cost agents with moderate efficacy or negligible additional benefits compared to existing treatments. The impending entry of generic versions for ZYTIGA and XTANDI is expected to lead to a decline in sales value.

Moreover, mCRPC treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the mCRPC market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the mCRPC market growth.

 

Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report

Discover more about mCRPC drugs in development @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials

Table of Contents

Related Reports

Metastatic Prostate Cancer Market 

Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.  

Metastatic Castration-Resistant Prostate Cancer Pipeline

Metastatic Castration-Resistant Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mCRPC companies, including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, among others.

Metastatic Castration-Sensitive Prostate Cancer Market

Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. 

Metastatic Castration-Sensitive Prostate Cancer Pipeline

Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key mCSPC companies, including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+91-9650213330
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/metastatic-castration-resistant-prostate-cancer-market-is-predicted-to-exhibit-remarkable-growth-at-a-cagr-of-7-5-during-the-study-period-20192032-estimates-delveinsight-302020065.html